Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
17 mrt 2008 - 07:36
Statutaire naam
Crucell N.V.
Titel
Crucell and DSM Biologics Announce Additional PER.C6® Licensing Agreement with MorphoSys
Bericht
Leiden, The Netherlands, 17 March 2008 - Dutch biotechnology company Crucell N.V. and DSM Biologics, a business unit of DSM Pharmaceutical Products, today announced that German-based MorphoSys AG has decided to extend the PER.C6® technology licensing agreement entered in September 2004, exercising an option for clinical and commercial production of antibodies. The extended license agreement allows MorphoSys to use the PER.C6® production platform for its proprietary therapeutic cancer antibody program MOR202, as well as for clinical and commercial production of MOR202. Financial details of the agreement were not disclosed.
Gerelateerde downloads
Datum laatste update: 08 januari 2026